These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

552 related items for PubMed ID: 19372255

  • 1. Loss of heterozygosity 4q24 and TET2 mutations associated with myelodysplastic/myeloproliferative neoplasms.
    Jankowska AM, Szpurka H, Tiu RV, Makishima H, Afable M, Huh J, O'Keefe CL, Ganetzky R, McDevitt MA, Maciejewski JP.
    Blood; 2009 Jun 18; 113(25):6403-10. PubMed ID: 19372255
    [Abstract] [Full Text] [Related]

  • 2. Mutation in TET2 in myeloid cancers.
    Delhommeau F, Dupont S, Della Valle V, James C, Trannoy S, Massé A, Kosmider O, Le Couedic JP, Robert F, Alberdi A, Lécluse Y, Plo I, Dreyfus FJ, Marzac C, Casadevall N, Lacombe C, Romana SP, Dessen P, Soulier J, Viguié F, Fontenay M, Vainchenker W, Bernard OA.
    N Engl J Med; 2009 May 28; 360(22):2289-301. PubMed ID: 19474426
    [Abstract] [Full Text] [Related]

  • 3. Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
    Fei F, Jariwala A, Pullarkat S, Loo E, Liu Y, Tizro P, Ali H, Otoukesh S, Amanam I, Artz A, Ally F, Telatar M, Nakamura R, Marcucci G, Afkhami M.
    Int J Mol Sci; 2024 Sep 23; 25(18):. PubMed ID: 39337700
    [Abstract] [Full Text] [Related]

  • 4. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
    Hahm C, Huh HJ, Mun YC, Seong CM, Chung WS, Huh J.
    Int J Lab Hematol; 2015 Apr 23; 37(2):181-9. PubMed ID: 24845343
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. TET2 deletions are a recurrent but rare phenomenon in myeloid malignancies and are frequently accompanied by TET2 mutations on the remaining allele.
    Bacher U, Weissmann S, Kohlmann A, Schindela S, Alpermann T, Schnittger S, Kern W, Haferlach T, Haferlach C.
    Br J Haematol; 2012 Jan 23; 156(1):67-75. PubMed ID: 22017486
    [Abstract] [Full Text] [Related]

  • 7. Impaired hydroxylation of 5-methylcytosine in myeloid cancers with mutant TET2.
    Ko M, Huang Y, Jankowska AM, Pape UJ, Tahiliani M, Bandukwala HS, An J, Lamperti ED, Koh KP, Ganetzky R, Liu XS, Aravind L, Agarwal S, Maciejewski JP, Rao A.
    Nature; 2010 Dec 09; 468(7325):839-43. PubMed ID: 21057493
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Mutations of e3 ubiquitin ligase cbl family members constitute a novel common pathogenic lesion in myeloid malignancies.
    Makishima H, Cazzolli H, Szpurka H, Dunbar A, Tiu R, Huh J, Muramatsu H, O'Keefe C, Hsi E, Paquette RL, Kojima S, List AF, Sekeres MA, McDevitt MA, Maciejewski JP.
    J Clin Oncol; 2009 Dec 20; 27(36):6109-16. PubMed ID: 19901108
    [Abstract] [Full Text] [Related]

  • 10. Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias.
    Abdel-Wahab O, Manshouri T, Patel J, Harris K, Yao J, Hedvat C, Heguy A, Bueso-Ramos C, Kantarjian H, Levine RL, Verstovsek S.
    Cancer Res; 2010 Jan 15; 70(2):447-52. PubMed ID: 20068184
    [Abstract] [Full Text] [Related]

  • 11. FISH analysis for TET2 deletion in a cohort of 362 Brazilian myeloid malignancies: correlation with karyotype abnormalities.
    de Oliveira FM, Miguel CE, Lucena-Araujo AR, de Lima AS, Falcão RP, Rego EM.
    Med Oncol; 2013 Mar 15; 30(1):483. PubMed ID: 23389918
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Targeted Next-Generation Sequencing in Myelodysplastic Syndrome and Chronic Myelomonocytic Leukemia Aids Diagnosis in Challenging Cases and Identifies Frequent Spliceosome Mutations in Transformed Acute Myeloid Leukemia.
    Reinig E, Yang F, Traer E, Arora R, Brown S, Rattray R, Braziel R, Fan G, Press R, Dunlap J.
    Am J Clin Pathol; 2016 Apr 15; 145(4):497-506. PubMed ID: 27124934
    [Abstract] [Full Text] [Related]

  • 17. Myeloid malignancies with acquired trisomy 21 as the sole cytogenetic change are clinically highly variable and display a heterogeneous pattern of copy number alterations and mutations.
    Larsson N, Lilljebjörn H, Lassen C, Johansson B, Fioretos T.
    Eur J Haematol; 2012 Feb 15; 88(2):136-43. PubMed ID: 21933280
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 28.